PCV45 - BUDGET IMPACT ANALYSIS OF ACEI AND ARBS II DRUGS IN PATIENTS WITH ARTERIAL HYPERTENSION

Abstract

To perform budget impact analysis of use of 8 drugs of antihypertensive group ACEI (fosinopril, lisinopril, ramipril and perindopril) and ARBS II (losartan, valsartan, candesartan and telmisartan) in patients with arterial hypertension in the Russian Federation for one year period. During the study the pharmacoeconomic model is developed based on data from randomized clinical trials that take into account the cost of treatment of patients with arterial hypertension. Method of pharmacoeconomic analysis: budget impact and direct costs analysis. For reference, we used the Euro currency as 1 EUR = 73 RUB. The prevalence of arterial hypertension in the Russian Federation exceeds 40% of the adult population. Total costs are calculated individually for each study drug. The analysis of direct costs shows that the treatment scheme with the use of ramipril is the most expensive (953 € per year per patient) and the treatment scheme using fosinopril is the least expensive (312 € per year per patient). During budget impact analysis time horizon of one year is used in accordance with the leaflets. In the calculations of budget impact analysis the possibility of the choice of a number of patients is supposed. To demonstrate the difference in costs between the compared treatment schemes, we calculated the options of transitions of the investigated drugs on fosinopril as on the comparator with the lowest total cost. The budget impact analysis shows that the use of fosinopril in the treatment of one patient with arterial hypertension in the year, compared with drugs: perindopril, ramipril, lisinopril, losartan, valsartan, candesartan and telmisartan can save from 69 € to 642 €.